Axsome 制药
AXSM
157.14
-4.65
-2.87%
Axsome 制药
US · AXSM
#1533 按市值排名
上市于 2015
157.14
-4.65
-2.87%
实时 - 追踪5344个代码 - 心跳于144秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例下降了1.0个百分点。
机构持股
- 机构持股比例
- 88.76% -1.02pp
- 机构数量
- 600 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund50.96%
Private Company16.65%
Hedge Fund12.03%
Public Company3.27%
VC/PE Fund2.35%
Government Pension Fund2.20%
Individual/Insider1.06%
Sovereign Wealth Fund0.98%
Insurance Company0.16%
Other10.34%
主要股东 截至 2026-04-14
Antecip Capital, L.L.C.
14.02% · 7.34M 股
BlackRock
5.93% · 3.10M 股
Vanguard Capital Management, LLC
4.29% · 2.24M 股
Vanguard Portfolio Management, LLC
3.79% · 1.98M 股
Invesco Ltd.
3.04% · 1.59M 股
FMR
2.94% · 1.54M 股
Geode Capital Management, LLC
1.85% · 967.17K 股
State Street Global Advisors
1.50% · 785.66K 股
Morgan Stanley
1.41% · 736.01K 股
Deep Track Capital, LP
1.34% · 700.00K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 21次买入 · 29次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Antecip Capital, L.L.C. | -- | 14.02% |
| Mark Coleman | Independent Director | 0.83% |
| Roger Jeffs | Lead Independent Director | 0.11% |
| Nick Pizzie | Chief Financial Officer | 0.08% |
| Mark Saad | Independent Director | 0.02% |
| Herriot Tabuteau | Chairperson & CEO | 0.01% |
| Susan Mahony | Director | 0.00% |
| Ari Maizel | Executive VP & Head of Commercial | -- |
| Mark Jacobson | COO & Secretary | -- |
| Hunter Murdock | General Counsel | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-02 | Mark Jacobson | COO & Secretary | Derivative Exercise and Sale | -10,000 | $12.95–208.65 |
| 2026-08-05 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,664 | $4.95–213.95 |
| 2026-08-05 | Herriot Tabuteau | Chairperson & CEO | Intent to Sell (Form 144) | -4,660 | $210.13 |
| 2026-08-04 | Herriot Tabuteau | Chairperson & CEO | Intent to Sell (Form 144) | -45,004 | $212.85 |
| 2026-06-30 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,666 | $4.95–240.25 |
| 2026-06-10 | Roger Jeffs | Lead Independent Director | Automatic Disposition | -572 | $246.18–249.12 |
| 2026-06-10 | Roger Jeffs | Lead Independent Director | Intent to Sell (Form 144) | -286 | $249.12 |
| 2026-06-09 | Roger Jeffs | Lead Independent Director | Intent to Sell (Form 144) | -286 | $246.18 |
| 2026-06-09 | Susan Mahony | Director | Derivative Exercise and Sale | -600 | $237.21–246.18 |
| 2026-06-09 | Susan Mahony | Director | Intent to Sell (Form 144) | -300 | $246.18 |
| 2026-06-09 | Mark Coleman | Independent Director | Derivative Exercise and Sale | -643 | $249.00 |
| 2026-06-09 | Mark Coleman | Independent Director | Intent to Sell (Form 144) | -643 | $249.00 |
| 2026-06-08 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,670 | $4.95–241.01 |
| 2026-06-08 | Susan Mahony | Director | Intent to Sell (Form 144) | -300 | $237.21 |
| 2026-06-08 | Nick Pizzie | Chief Financial Officer | Derivative Exercise and Sale | -33,000 | $3.50–240.09 |
| 2026-06-07 | Roger Jeffs | Lead Independent Director | Derivative Exercise and Retained | +1,429 | -- |
| 2026-06-07 | Mark Saad | Independent Director | Derivative Exercise and Retained | +1,429 | -- |
| 2026-06-07 | Susan Mahony | Director | Derivative Exercise and Retained | +829 | -- |
| 2026-06-07 | Mark Coleman | Independent Director | Derivative Exercise and Retained | +786 | -- |
| 2026-06-04 | Roger Jeffs | Lead Independent Director | Other Derivative Acquisition | +1,721 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Axsome 制药 讨论区 0 条评论